Home > Insider Trading > Filing (0001104659-14-074934)

Filing Details

Accession Number:: 0001104659-14-074934
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-10-29 18:38:09
Reporting Period:: 2014-10-27

Filing Date:: 2014-10-29
Accepted Time:: 2014-10-29 18:38:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1359931	Proteon Therapeutics Inc	PRTO	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1526068	Timothy Haines	C/O Abingworth Llp 38 Jermyn Street London X0 SW1Y 6DN		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-10-27	950,000	$10.00	950,000	No	4	P	Indirect	By Abingworth Bioventures VI, LP
Common Stock	Acquisiton	2014-10-27	1,067,872	$0.00	2,017,872	No	4	C	Indirect	By Abingworth Bioventures VI, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Abingworth Bioventures VI, LP
No	4	C	Indirect	By Abingworth Bioventures VI, LP

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Convertible Preferred Stock	Disposition	2014-10-27	16,044,081	$0.00	1,010,969	$0.00
Series D Convertible Preferred Stock	Option (Right to Purchase)	Disposition	2014-10-27	12,835,264	$0.00	808,775	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	J	Indirect

Footnotes

These shares were purchased in connection with the Issuer's initial public offering of Common Stock.
The shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Upon the closing of the Issuer's initial public offering, each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a one-for-one basis (without payment of further consideration and with no expiration date) plus an additional 56,903 incremental shares as a result of an adjustment as provided for in the Company's certificate of incorporation.
Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014.
Abingworth had a right to purchase shares of Series D Convertible Preferred Stock under the Series D Purchase Agreement at a price of $0.588656, which right to purchase ceased to be exercisable upon the initial filing of the Issuer's registration statement for its initial public offering, and terminated upon the completion of the Issuer's initial public offering of Common Stock. Each share of Series D Preferred Stock issuable upon exercise of the right to purchase would have been convertible into shares of the Issuer's common stock as described in footnote (3) above.